A follow up on the feasibility after national implementation of magnesium sulfate for neuroprotection prior to preterm birth.

导出 OA

翻译打印收藏纠错

作者： Sara,Hellström ^[1] ; Andrea,Jonsdotter ^[2] ; Maria,Jonsson ^[1] ; Karin,Pettersson ^[3] ; Sissel,Saltvedt ^[4] ; Andreas,Herbst ^[5] ; Johan,Ågren ^[6] ; Ulrika,Ådén ^[7] ; Magnus,Domellöf ^[4] ; Henrik,Hagberg ^[6] ; Ylva,Carlsson ^[8]

作者单位： Department of Obstetrics and Gynecology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden. ^[1] Division of Neonatology, Department of Pediatrics, The Queen Silvia Children's Hospital, Sahlgrenska University Hospital, Gothenburg, Sweden. ^[2] Center of Perinatal Medicine and Health, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. ^[3] Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden. ^[4] Clinical Intervention Science and Technology, CLINTEC, Karolinska Institute, Stockholm, Sweden. ^[5] Department of Women's and Children's Health, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. ^[6] Department of Obstetrics and Gynecology, Skåne University Hospital, Institution for Clinical Sciences Lund, Lund University, Lund, Sweden. ^[7] Department of Biomedical and Clinical SCIENCES, Linköping University, Linköping, Sweden. ^[8] Department of Clinical Sciences, Pediatrics, Umeå University, Umeå, Sweden. ^[9]

关键词 cerebral palsy extremely preterm magnesium sulfate neuroprotection premature birth preterm birth very preterm